|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar
|
|
3
|
Chen R, Manochakian R, James L, Azzouqa
AG, Shi H, Zhang Y, Zhao Y, Zhou K and Lou Y: Emerging therapeutic
agents for advanced non-small cell lung cancer. J Hematol Oncol.
13:582020. View Article : Google Scholar
|
|
4
|
Sharma P, Wagner K, Wolchok JD and Allison
JP: Novel cancer immunotherapy agents with survival benefit: Recent
successes and next steps. Nat Rev Cancer. 11:805–812. 2011.
View Article : Google Scholar
|
|
5
|
Horvath L, Thienpont B, Zhao L, Wolf D and
Pircher A: Overcoming immunotherapy resistance in non-small cell
lung cancer (NSCLC)-novel approaches and future outlook. Mol
Cancer. 19:1412020. View Article : Google Scholar
|
|
6
|
Vasilakos JP and Tomai MA: The use of
toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev
Vaccines. 12:809–819. 2013. View Article : Google Scholar
|
|
7
|
Adams S: Toll-like receptor agonists in
cancer therapy. Immunotherapy. 1:949–964. 2009. View Article : Google Scholar
|
|
8
|
Urban-Wojciuk Z, Khan MM, Oyler BL,
Fahraeus R, Marek-Trzonkowska N, Nita-Lazar A, Hupp TR and Goodlett
DR: The role of TLRs in anti-cancer immunity and tumor rejection.
Front Immunol. 10:23882019. View Article : Google Scholar
|
|
9
|
Lim KH: TLR7 and TLR8, Resiquimod, and
852A. Cancer Therapeutic Targets. Marshall J: Springer; New York,
NY: pp. 1–8. 2013
|
|
10
|
Schön MP and Schön M: TLR7 and TLR8 as
targets in cancer therapy. Oncogene. 27:190–199. 2008. View Article : Google Scholar
|
|
11
|
Zhou Z, Yu X, Zhang J, Tian Z and Zhang C:
TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell
anti-tumor effects in hepatocellular carcinoma. Cancer Lett.
369:298–306. 2015. View Article : Google Scholar
|
|
12
|
Yin T, He S and Wang Y: Toll-like receptor
7/8 agonist, R848, exhibits antitumoral effects in a breast cancer
model. Mol Med Rep. 12:3515–3520. 2015. View Article : Google Scholar
|
|
13
|
Rook AH, Gelfand JM, Wysocka M, Troxel AB,
Benoit B, Surber C, Elenitsas R, Buchanan MA, Leahy DS, Watanabe R,
et al: Topical resiquimod can induce disease regression and enhance
T-cell effector functions in cutaneous T-cell lymphoma. Blood.
126:1452–1461. 2015. View Article : Google Scholar
|
|
14
|
Killock D: Haematological cancer:
Resiquimod-a topical CTCL therapy. Nat Rev Clin Oncol. 12:5632015.
View Article : Google Scholar
|
|
15
|
Koh J, Kim S, Lee SN, Kim SY, Kim JE, Lee
KY, Kim MS, Heo JY, Park YM, Ku BM, et al: Therapeutic efficacy of
cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8
agonist in lung cancer model. Nanomedicine. 37:1024152021.
View Article : Google Scholar
|
|
16
|
Li F, Zheng X, Wang X, Xu J and Zhang Q:
Macrophage polarization synergizes with oxaliplatin in lung cancer
immunotherapy via enhanced tumor cell phagocytosis. Transl Oncol.
14:1012022021. View Article : Google Scholar
|
|
17
|
Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ,
Fagnano E, Klein C, Honeychurch J and Illidge TM: A TLR7 agonist
enhances the antitumor efficacy of obinutuzumab in murine lymphoma
models via NK cells and CD4 T cells. Leukemia. 31:1611–1621. 2017.
View Article : Google Scholar
|
|
18
|
Gallotta M, Assi H, Degagne E, Kannan SK,
Coffman RL and Guiducci C: Inhaled TLR9 agonist renders lung tumors
permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T
cell interplay. Cancer Res. 78:4943–4956. 2018. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Alam MM, Yang D, Trivett A, Meyer TJ and
Oppenheim JJ: HMGN1 and R848 synergistically activate dendritic
cells using multiple signaling pathways. Front Immunol. 9:29822018.
View Article : Google Scholar
|
|
21
|
Frega G, Wu Q, Le Naour J, Vacchelli E,
Galluzzi L, Kroemer G and Kepp O: Trial watch: Experimental
TLR7/TLR8 agonists for oncological indications. Oncoimmunology.
9:17960022020. View Article : Google Scholar
|
|
22
|
Lu R, Groer C, Kleindl PA, Moulder KR,
Huang A, Hunt JR, Cai S, Aires DJ, Berkland C and Forrest ML:
Formulation and preclinical evaluation of a toll-like receptor 7/8
agonist as an anti-tumoral immunomodulator. J Control Release.
306:165–176. 2019. View Article : Google Scholar
|
|
23
|
Cen X, Liu S and Cheng K: The role of
toll-like receptor in inflammation and tumor immunity. Front
Pharmacol. 9:8782018. View Article : Google Scholar
|
|
24
|
Akira S, Takeda K and Kaisho T: Toll-like
receptors: Critical proteins linking innate and acquired immunity.
Nat Immunol. 2:675–680. 2001. View
Article : Google Scholar
|
|
25
|
Moingeon P, Haensler J and Lindberg A:
Towards the rational design of Th1 adjuvants. Vaccine.
19:4363–4372. 2001. View Article : Google Scholar
|
|
26
|
Michaelis KA, Norgard MA, Zhu X, Levasseur
PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Ramos
DMA, et al: The TLR7/8 agonist R848 remodels tumor and host
responses to promote survival in pancreatic cancer. Nat Commun.
10:46822019. View Article : Google Scholar
|
|
27
|
Hosoya T, Sato-Kaneko F, Ahmadi A, Yao S,
Lao F, Kitaura K, Matsutani T, Carson DA and Hayashi T: Induction
of oligoclonal CD8 T cell responses against pulmonary metastatic
cancer by a phospholipid-conjugated TLR7 agonist. Proc Natl Acad
Sci USA. 115:E6836–E6844. 2018. View Article : Google Scholar
|
|
28
|
Karimi K, Boudreau J, Fraser K, Liu H,
Delanghe J, Gauldie J, Xing Z, Bramson JL and Wan Y: Enhanced
antitumor immunity elicited by dendritic cell vaccines is a result
of their ability to engage both CTL and IFN gamma-producing NK
cells. Mol Ther. 16:411–418. 2008. View Article : Google Scholar
|
|
29
|
Stojanovic A and Cerwenka A: Natural
killer cells and solid tumors. J Innate Immun. 3:355–364. 2011.
View Article : Google Scholar
|
|
30
|
Gotwals P, Cameron S, Cipolletta D,
Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S,
Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining
targeted and conventional cancer therapy with immunotherapy. Nat
Rev Cancer. 17:286–301. 2017. View Article : Google Scholar
|
|
31
|
Meador CB and Hata AN: Acquired resistance
to targeted therapies in NSCLC: Updates and evolving insights.
Pharmacol Ther. 210:1075222020. View Article : Google Scholar
|
|
32
|
Wang D, Precopio M, Lan T, Yu D, Tang JX,
Kandimalla ER and Agrawal S: Antitumor activity and immune response
induction of a dual agonist of toll-like receptors 7-8. Mol Cancer
Ther. 9:1788–1797. 2010. View Article : Google Scholar
|
|
33
|
Pandey S, Kawai T and Akira S: Microbial
sensing by toll-like receptors and intracellular nucleic acid
sensors. Cold Spring Harb Perspect Biol. 7:a0162462014. View Article : Google Scholar
|
|
34
|
Petes C, Odoardi N and Gee K: The toll for
trafficking: Toll-like receptor 7 Delivery to the endosome. Front
Immunol. 8:10752017. View Article : Google Scholar
|
|
35
|
Smith AA, Gale EC, Roth GA, Maikawa CL,
Correa S, Yu AC and Appel EA: Nanoparticles presenting potent
TLR7/8 agonists enhance Anti-PD-L1 immunotherapy in cancer
treatment. Biomacromolecules. 21:3704–3712. 2020. View Article : Google Scholar
|
|
36
|
Bahmani B, Gong H, Luk BT, Haushalter KJ,
DeTeresa E, Previti M, Zhou J, Gao W, Bui JD, Zhang L, et al:
Intratumoral immunotherapy using platelet-cloaked nanoparticles
enhances antitumor immunity in solid tumors. Nat Commun.
12:19992021. View Article : Google Scholar
|
|
37
|
Rodell CB, Ahmed MS, Garris CS, Pittet MJ
and Weissleder R: Development of adamantane-conjugated TLR7/8
agonists for supramolecular delivery and cancer immunotherapy.
Theranostics. 9:8426–8436. 2019. View Article : Google Scholar
|
|
38
|
Goliwas K, Deshane J, Elmets C and Athar
M: Moving immune therapy forward targeting TME. Physiol Rev.
101:417–425. 2021. View Article : Google Scholar
|
|
39
|
Taube JM, Galon J, Sholl LM, Rodig SJ,
Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL and
Cimino-Mathews A: Implications of the tumor immune microenvironment
for staging and therapeutics. Mod Pathol. 31:214–234. 2018.
View Article : Google Scholar
|
|
40
|
Rodell CB, Arlauckas SP, Cuccarese MF,
Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ and Weissleder R:
TLR7/8-agonist-loaded nanoparticles promote the polarization of
tumour-associated macrophages to enhance cancer immunotherapy. Nat
Biomed Eng. 2:578–588. 2018. View Article : Google Scholar
|
|
41
|
Durgeau A, Virk Y, Corgnac S and
Mami-Chouaib F: Recent advances in targeting CD8 T-cell immunity
for more effective cancer immunotherapy. Front Immunol. 9:142018.
View Article : Google Scholar
|
|
42
|
Zahm CD, Colluru VT, McIlwain SJ, Ong IM
and McNeel DG: TLR stimulation during T-cell activation lowers PD-1
expression on CD8(+) T cells. Cancer Immunol Res. 6:1364–1374.
2018. View Article : Google Scholar
|
|
43
|
Dajon M, Iribarren K and Cremer I: Dual
roles of TLR7 in the lung cancer microenvironment. Oncoimmunology.
4:e9916152015. View Article : Google Scholar
|
|
44
|
Chatterjee S, Crozet L, Damotte D,
Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc
J, Katsahian S, et al: TLR7 promotes tumor progression,
chemotherapy resistance, and poor clinical outcomes in non-small
cell lung cancer. Cancer Res. 74:5008–5018. 2014. View Article : Google Scholar
|
|
45
|
Cherfils-Vicini J, Platonova S, Gillard M,
Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F,
Dieu-Nosjean MC, Fridman WH, et al: Triggering of TLR7 and TLR8
expressed by human lung cancer cells induces cell survival and
chemoresistance. J Clin Invest. 120:1285–1297. 2010. View Article : Google Scholar
|
